From: newswise.com There are two surgical options to treat breast cancer: lumpectomy and mastectomy. But there are many more reasons why women choose one over another, says Sarah McLaughlin, M.D., a breast surgical oncologist and chair of the Department of Surgery at Mayo Clinic in Jacksonville, Florida. “Some of that can be cancer-based, some of it can be family history and …
5 questions to ask a breast cancer surgeon
From: roswellpark.org What to learn about their experience, advanced options they provide and more — before deciding where to seek cancer care. If you’ve been diagnosed with breast cancer, surgery will likely be a primary part of your treatment. You’ll want to choose a surgeon and cancer center with the tools and expertise to deliver the best outcomes for your …
RK-33 May Be Significant in Treatment of Breast Cancer Bone Metastasis
By: Gillian McGovern From: pharmacytimes.com Key Takeaways RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis. In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects. A study published in Cancer Letters demonstrated new promise in the treatment of breast cancer bone metastasis, or breast cancer that …
Beyond the Pink Ribbon: A Closer Look at Breast Cancer Progress
By: Sabrina Serani From: targetedonc.com Breast cancer remains a significant health challenge worldwide. Despite advancements in treatment, many women continue to face its devastating impact. In an interview with Targeted OncologyTM, Oranus Mohammadi, MD, medical oncologist at The Oncology Institute of Hope & Innovation, discussed the remarkable progress made in improving survival rates for patients with breast cancer. She delved …
Novel approach combines glutaminase and HuR blockade to suppress breast cancer growth
Source: São Paulo Research Foundationt From: news-medical.net A study led by Brazilian researchers and reported in an article published in the journal Nature Communications proposes that simultaneously targeting the enzyme glutaminase and the protein HuR, both of which are essential to tumor progression, may be effective in treating breast cancer. The metabolic requirements of tumor cells are associated with high levels of glutamine consumption …
Extended estrogen suppression treatment found safe for postmenopausal breast cancer patients
Source:Elsevier From: news-medical.net New evidence shows that extended estrogen suppression treatment using an aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of coronary artery calcification, a sign of active coronary atherosclerosis, as some prior studies had indicated. An article in the Canadian Journal of Cardiology, published by Elsevier, details the findings from …
UCLA team develops automated HER2 scoring system with deep learning and pyramid sampling
From: news-medical.net HER2 is a critical protein that plays a pivotal role in breast cancer cell growth and aggressiveness. Its expression level is a key indicator for treatment decisions, including the use of HER2-targeted therapies. Currently, HER2 status assessment relies heavily on immunohistochemical (IHC) staining of tissue slides followed by manual inspection by pathologists. This process, though widely adopted, suffers …
When is the best time of day for cancer treatment?
From: eurekalert.org Researchers from Charité are developing new methods to use the internal clock inside tumor cells to optimize cancer therapies How effective medications are depends on various factors, including the time of day when they are administered. Why? Because our bodies don’t always function exactly the same. Instead, they follow the cycle set by their internal clock, otherwise known …
The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts
By: Ashling Wahner From: onclive.com Ongoing research may solidify the roles of oral selective estrogen receptor degraders (SERDs), PARP inhibitors, and additional targeted therapies, particularly after progression in CDK4/6 inhibitors, in the management of hormone receptor (HR)–positive breast cancer, according to Shipra Gandhi, MD. “We are living in an interesting era where we have multiple options available for patients [with …
An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?
By: Caroline Seymour From: onclive.com The decision support that is currently available to community oncologists has made it tremendously difficult to keep pace with what many consider to be monumental advances in the understanding and management of breast and lung cancers, according to Maurie Markman, MD. He added that the momentum driving drug discovery is unlikely to ease up, leaving …